Get the Stockscreener App
64.92
0.87%
-0.57
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $64.92, with a volume of 1.94M.
It is down -0.87% in the last 24 hours and down -17.56% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$65.49
Open:
$66.21
24h Volume:
1.94M
Relative Volume:
1.79
Market Cap:
$10.26B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
69.06
EPS:
0.94
Net Cash Flow:
$245.03M
1W Performance:
-1.55%
1M Performance:
-17.56%
6M Performance:
-10.64%
1Y Performance:
-9.48%
1-Day Range:
$64.58
$66.87
1-Week Range:
$63.51
$67.19
52-Week Range:
$61.16
$85.57
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
(612) 379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
64.92 | 10.26B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
Bio-Techne Expands RNAscope Probes For Human And Mouse Transcriptome In Spatial Biology - Nasdaq
Bio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology - Quantisnow
Deep Dive Into Bio-Techne Stock: Analyst Perspectives (4 Ratings) - Benzinga
Bio-Techne downgraded to Neutral from Outperform at Baird - TipRanks
Bio-Techne launches GMP TcBuster for cell therapy development By Investing.com - Investing.com Nigeria
Bio-Techne director Amy Herr sells $122,690 in stock By Investing.com - Investing.com Nigeria
Bio-Techne director Amy Herr sells $122,690 in stock - Investing.com India
Bio-Techne Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart
Bio-Techne Stock Outlook: Is Wall Street Bullish or Bearish? - Inkl
Bio-Techne's (NASDAQ:TECH) Soft Earnings Don't Show The Whole Picture - Yahoo Finance
Bio-Techne launches GMP TcBuster for cell therapy development - Investing.com India
Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System - Yahoo Finance
Mirae Asset Global Investments Co. Ltd. Increases Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Earnings call transcript: Bio-Techne Q4 2024 beats EPS forecast By Investing.com - Investing.com Nigeria
Allspring Global Investments Holdings LLC Has $52.64 Million Stake in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Q4 Earnings Estimate for Bio-Techne Issued By William Blair - MarketBeat
Earnings call transcript: Bio-Techne Q4 2024 beats EPS forecast - Investing.com
Q4 EPS Estimates for Bio-Techne Decreased by Leerink Partnrs - MarketBeat
Bio-Techne (NASDAQ:TECH) Shares Gap DownHere's What Happened - MarketBeat
Brokerages Set Bio-Techne Co. (NASDAQ:TECH) Price Target at $86.57 - MarketBeat
4,474 Shares in Bio-Techne Co. (NASDAQ:TECH) Bought by Summit Trail Advisors LLC - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Position Reduced by State of Alaska Department of Revenue - MarketBeat
Stephens Investment Management Group LLC Has $52.92 Million Stock Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Corporation: How Spatial Biology and Molecular Diagnostics Are Changing the Game! - Smartkarma
Ex-Dividend Reminder: Cencora, Bio-Techne and Eli Lilly - Nasdaq
Bio-Techne Corp. stock underperforms Monday when compared to competitors - MSN
Bio-Techne Co. (NASDAQ:TECH) Shares Acquired by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Bio-Techne (NASDAQ:TECH) Price Target Raised to $90.00 - MarketBeat
Bio-Techne (NASDAQ:TECH) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Bio-Techne (NASDAQ:TECH) Shares Gap Up After Dividend Announcement - MarketBeat
TECH Gears Up to Report Q2 Earnings: Here's What to Expect - MSN
KeyCorp Issues Positive Forecast for Bio-Techne (NASDAQ:TECH) Stock Price - MarketBeat
Bio-Techne (NASDAQ:TECH) Given New $80.00 Price Target at Royal Bank of Canada - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Cor - GuruFocus.com
Trust Point Inc. Buys 7,333 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Corp. stock underperforms Friday when compared to competitors - MarketWatch
Bio-Techne Appoints Dr. Amy E. Herr as Independent Director and Announces DividendOn January 30, 2025, Bio-Techne Corporation (NASDAQ: TECH) took steps to enhance its Board of Directors with the appointment of Dr. Amy E. Herr as an independent di - Defense World
Conestoga Capital Advisors LLC Buys 5,025 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Corp (TECH) reports earnings - Quartz
BIO-TECHNE Corp SEC 10-Q Report - TradingView
3 Genomics Stocks Unlocking the Future of Medicine - Inkl
There is no doubt that Bio-Techne Corp (TECH) ticks all the boxes. - SETE News
Bio-Techne Corporation (NASDAQ:TECH) Q2 2025 Earnings Call Transcript - Insider Monkey
Bio-Techne beats Q2 earnings estimates on improving demand for biotech products - ETHealthWorld
Bio-Techne Corp (TECH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - GuruFocus.com
Bio-Techne Corp (TECH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bio Techne Corp Stock (TECH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Herr Amy E. | Director |
Feb 14 '25 |
Sale |
65.96 |
1,860 |
122,691 |
1,976 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):